HMGB1 and osteosarcoma: They found that HMGB1 was targeted by miR-22, miR-218, miR-26a, miR-34a, miR-129-5p, and miR-142-3p to sensitize osteosarcoma, endometrial carcinoma, melanoma, retinoblastoma, breast cancer, NSCLC to chemotherapeutic agents through inhibiting autophagy (146–151).